EZH2 and head and neck squamous cell carcinoma: Another study showed that targeting EZH2 inhibits epithelial–mesenchymal transition (EMT) in HPV-negative HNSCC through downregulation of the expression of EMT-related markers such as N-cadherin and vimentin, but via upregulating E-cadherin [44].